Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

A novel class of ion displacement ligands as antagonists of the αIIbβ3 receptor that limit conformational reorganization of the receptor.

Jiang JK, McCoy JG, Shen M, LeClair CA, Huang W, Negri A, Li J, Blue R, Harrington AW, Naini S, David G 3rd, Choi WS, Volpi E, Fernandez J, Babayeva M, Nedelman MA, Filizola M, Coller BS, Thomas CJ.

Bioorg Med Chem Lett. 2014 Feb 15;24(4):1148-53. doi: 10.1016/j.bmcl.2013.12.122. Epub 2014 Jan 8.

2.

GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.

Armstrong PC, Peter K.

Thromb Haemost. 2012 May;107(5):808-14. doi: 10.1160/TH11-10-0727. Epub 2012 Feb 28. Review.

PMID:
22370973
3.

Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.

Sall DJ, Arfsten AE, Bastian JA, Denney ML, Harms CS, McCowan JR, Morin JM Jr, Rose JW, Scarborough RM, Smyth MS, Um SL, Utterback BG, Vasileff RT, Wikel JH, Wyss VL, Jakubowski JA.

J Med Chem. 1997 Aug 29;40(18):2843-57.

PMID:
9288166
4.

Structure-based virtual screening of small-molecule antagonists of platelet integrin αIIbβ3 that do not prime the receptor to bind ligand.

Negri A, Li J, Naini S, Coller BS, Filizola M.

J Comput Aided Mol Des. 2012 Sep;26(9):1005-15. doi: 10.1007/s10822-012-9594-6. Epub 2012 Aug 15.

5.

Allicin and disulfiram enhance platelet integrin alphaIIbbeta3-fibrinogen binding.

Manaster Y, Shenkman B, Rosenberg N, Savion N.

Thromb Res. 2009 Sep;124(4):477-82. doi: 10.1016/j.thromres.2009.06.019. Epub 2009 Jul 26.

PMID:
19632706
6.

αIIbβ3: structure and function.

Coller BS.

J Thromb Haemost. 2015 Jun;13 Suppl 1:S17-25. doi: 10.1111/jth.12915. Review.

7.

Preparation and biological activity of novel tricyclic GPIIb/IIIa antagonists.

Robarge KD, Dina MS, Somers TC, Lee A, Rawson TE, Olivero AG, Tischler MH, Webb RR 2nd, Weese KJ, Aliagas I, Blackburn BK.

Bioorg Med Chem. 1998 Dec;6(12):2345-81.

PMID:
9925295
8.

Tailoring of integrin ligands: probing the charge capability of the metal ion-dependent adhesion site.

Bollinger M, Manzenrieder F, Kolb R, Bochen A, Neubauer S, Marinelli L, Limongelli V, Novellino E, Moessmer G, Pell R, Lindner W, Fanous J, Hoffman A, Kessler H.

J Med Chem. 2012 Jan 26;55(2):871-82. doi: 10.1021/jm2013826. Epub 2012 Jan 9.

PMID:
22185640
9.

Differential antiplatelet effects of various glycoprotein IIb-IIIa antagonists.

Dickfeld T, Ruf A, Pogatsa-Murray G, Müller I, Engelmann B, Taubitz W, Fischer J, Meier O, Gawaz M.

Thromb Res. 2001 Jan 15;101(2):53-64.

PMID:
11342206
10.

Integrin alphaIIbbeta3 and its antagonism.

Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF.

Arterioscler Thromb Vasc Biol. 2003 Jun 1;23(6):945-52. Epub 2003 Mar 13. Review. Erratum in: Arterioscler Thromb Vasc Biol. 2003 Sep;23(9):1705.

11.

Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors.

Peter K, Schwarz M, Ylänne J, Kohler B, Moser M, Nordt T, Salbach P, Kübler W, Bode C.

Blood. 1998 Nov 1;92(9):3240-9.

12.

RUC-4: a novel αIIbβ3 antagonist for prehospital therapy of myocardial infarction.

Li J, Vootukuri S, Shang Y, Negri A, Jiang JK, Nedelman M, Diacovo TG, Filizola M, Thomas CJ, Coller BS.

Arterioscler Thromb Vasc Biol. 2014 Oct;34(10):2321-9. doi: 10.1161/ATVBAHA.114.303724. Epub 2014 Aug 21.

13.

Integrin alphaIIbbeta3-specific synthetic human monoclonal antibodies and HCDR3 peptides that potently inhibit platelet aggregation.

Chung J, Rader C, Popkov M, Hur YM, Kim HK, Lee YJ, Barbas CF 3rd.

FASEB J. 2004 Feb;18(2):361-3. Epub 2003 Dec 19.

PMID:
14688205
14.

Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors.

Jennings LK, White MM.

Am Heart J. 1998 May;135(5 Pt 2 Su):S179-83. Review.

PMID:
9588397
15.

Dissociation of glycoprotein IIb/IIIa antagonists from platelets does not result in fibrinogen binding or platelet aggregation.

Frelinger AL 3rd, Furman MI, Krueger LA, Barnard MR, Michelson AD.

Circulation. 2001 Sep 18;104(12):1374-9.

16.

Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.

Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.

Thromb Haemost. 2000 Jun;83(6):915-22.

PMID:
10896249
17.

Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.

Karim ZA, Vemana HP, Alshbool FZ, Lin OA, Alshehri AM, Javaherizadeh P, Paez Espinosa EV, Khasawneh FT.

Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):637-44. doi: 10.1161/ATVBAHA.114.304509. Epub 2015 Jan 15. Erratum in: Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):e50.

18.

Effects of ligand-mimetic peptides Arg-Gly-Asp-X (X = Phe, Trp, Ser) on alphaIIbbeta3 integrin conformation and oligomerization.

Hantgan RR, Paumi C, Rocco M, Weisel JW.

Biochemistry. 1999 Nov 2;38(44):14461-74.

PMID:
10545168
19.

Ring constrained analogues of beta-alanine-containing GPIIb/IIIa receptor antagonists.

Sielecki TM, Wityak J, Liu J, Mousa SA, Thoolen M, Wexler RR, Olson RE.

Bioorg Med Chem Lett. 2000 Mar 6;10(5):449-52.

PMID:
10743945
20.

Variation in one residue associated with the metal ion-dependent adhesion site regulates αIIbβ3 integrin ligand binding affinity.

Raborn J, Fu T, Wu X, Xiu Z, Li G, Luo BH.

PLoS One. 2013 Oct 8;8(10):e76793. doi: 10.1371/journal.pone.0076793. eCollection 2013 Oct 8.

Supplemental Content

Support Center